Acute coronary syndromes: Rivaroxaban reduces serious CV events without increasing fatal bleeding in patients with a recent ACS
- PMID: 22124321
- DOI: 10.1038/nrcardio.2011.181
Acute coronary syndromes: Rivaroxaban reduces serious CV events without increasing fatal bleeding in patients with a recent ACS
Comment on
-
Rivaroxaban in patients with a recent acute coronary syndrome.N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077192 Clinical Trial.
Similar articles
-
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).Am J Cardiol. 2018 Dec 1;122(11):1896-1901. doi: 10.1016/j.amjcard.2018.08.034. Epub 2018 Sep 7. Am J Cardiol. 2018. PMID: 30340765 Clinical Trial.
-
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.J Am Coll Cardiol. 2018 Jul 10;72(2):129-136. doi: 10.1016/j.jacc.2018.04.055. J Am Coll Cardiol. 2018. PMID: 29976285 Clinical Trial.
-
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.Lancet. 2017 May 6;389(10081):1799-1808. doi: 10.1016/S0140-6736(17)30751-1. Epub 2017 Mar 18. Lancet. 2017. PMID: 28325638 Clinical Trial.
-
Rivaroxaban for the treatment of acute coronary syndromes.Expert Opin Pharmacother. 2013 May;14(7):917-27. doi: 10.1517/14656566.2013.780029. Epub 2013 Apr 2. Expert Opin Pharmacother. 2013. PMID: 23544968 Review.
-
Potential role of rivaroxaban in patients with acute coronary syndrome.Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Drug Des Devel Ther. 2012. PMID: 23209364 Free PMC article. Review.
References
-
- N Engl J Med. 2012 Jan 5;366(1):9-19 - PubMed
Publication types
LinkOut - more resources
Full Text Sources